{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-126487","form_type":"8-K","ticker":"ICU","cik":"0001831868","company_name":"SeaStar Medical Holding Corp","filed_at":"2024-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.906028+00:00","generated_at":"2026-05-30T01:04:37.030767+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"SeaStar Medical reports Q3 revenue of $67,500 from first commercial sales of QUELIMMUNE; net loss narrows to $4.5M","bullets":["First commercial revenue of $67,500 from direct QUELIMMUNE shipments to hospital customer; no revenue in Q3 2023.","Net loss $4.5M ($1.10/share) vs $7.2M ($9.02/share) in Q3 2023; cash $2.1M as of Sep 30.","Eliminated all $9M+ long-term debt during 2024; no long-term debt outstanding.","FDA granted Breakthrough Device Designation for SCD in chronic dialysis (4th designation).","NEUTRALIZE-AKI adult trial: 59 subjects enrolled, record October enrollment; 12 clinical sites."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-126487","json":"https://secwatch.observer/filing/0000950170-24-126487.json","markdown":"https://secwatch.observer/filing/0000950170-24-126487.md","text":"https://secwatch.observer/filing/0000950170-24-126487.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1831868/000095017024126487/0000950170-24-126487-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1831868/000095017024126487/icu-20241113.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T01:04:37.030767+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}